| TOPICAL REVIEW |
|
| Year : 2017 | Volume
: 12
| Issue : 1 | Page : 48-51 |
|
|
New treatments for systemic lupus erythematosus
Robert George Lahita
Department of Medicine, Newark Beth Israel Medical Center, Rutgers, The NJ Medical School, Newark, New Jersey, USA
Correspondence Address:
Robert George Lahita
Rutgers, New Jersey Medical School, Newark, New Jersey
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/injr.injr_1_17
|
|
|
New therapies for systemic lupus erythematosus are rare. This is because of the complexity of the disease and its varied presentations. There are many variables and a variety of measurement scales that must be satisfied before a new agent is approved for use in humans. Attempts are ongoing to develop biological treatments for the disease using three approaches: B cell modulation, T cell regulation and cytokine inhibition. This paper reviews the current state of these three critical areas. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
